Novocure Stock Today
| NVCR Stock | USD 19.49 0.57 2.84% |
PerformanceVery Weak
| Odds Of DistressLow
|
Novocure is selling at 19.49 as of the 16th of March 2025; that is 2.84 percent decrease since the beginning of the trading day. The stock's lowest day price was 19.31. Novocure has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 16th of December 2024 and ending today, the 16th of March 2025. Click here to learn more.
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. The company has 109.92 M outstanding shares of which 5.2 M shares are now shorted by private and institutional investors with about 5.65 trading days to cover. More on Novocure
Moving together with Novocure Stock
Moving against Novocure Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Novocure Stock Highlights
| CEO and Director | Asaf Danziger |
| Thematic Ideas | (View all Themes) |
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, NASDAQ Composite Total, Medical Equipment, Cancer Fighters, Health Care, Health Care Equipment & Supplies, Medical Instruments & Supplies, Healthcare (View all Sectors) |
| Financial Strength | |
Novocure (NVCR) is traded on NASDAQ Exchange in USA. It is located in Neuhofstrasse 21, Baar, Switzerland, 6340 and employs 1,488 people. Novocure is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.14 B. Novocure conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 109.92 M outstanding shares of which 5.2 M shares are now shorted by private and institutional investors with about 5.65 trading days to cover.
Novocure currently holds about 948.52 M in cash with (26.37 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.06.
Check Novocure Probability Of Bankruptcy
Ownership AllocationNovocure maintains a total of 109.92 Million outstanding shares. The majority of Novocure outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Novocure to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Novocure. Please pay attention to any change in the institutional holdings of Novocure as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Novocure Ownership Details
Novocure Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Novocure market risk premium is the additional return an investor will receive from holding Novocure long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0.22) | |||
| Jensen Alpha | (0.77) | |||
| Total Risk Alpha | (0.40) | |||
| Treynor Ratio | 14.75 |
Novocure Stock Against Markets
Novocure Corporate Management
| Piet MD | Head VP | Profile | |
| Barak BenArye | General Counsel | Profile | |
| William Burke | Chief Officer | Profile | |
| Frank Leonard | Executive Oncology | Profile | |
| Christoph Brackmann | Chief Officer | Profile | |
| Uri MD | Chief Officer | Profile |
Additional Tools for Novocure Stock Analysis
When running Novocure's price analysis, check to measure Novocure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novocure is operating at the current time. Most of Novocure's value examination focuses on studying past and present price action to predict the probability of Novocure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novocure's price. Additionally, you may evaluate how the addition of Novocure to your portfolios can decrease your overall portfolio volatility.